HIV DALAM KEHAMILAN

Helwinofira Helwinofira; Soufni Morawati

doi:10.59003/nhj.v6i1.2144

Authors

Helwinofira Helwinofira Universitas Baiturrahmah
Soufni Morawati Universitas Baiturrahmah

DOI:

https://doi.org/10.59003/nhj.v6i1.2144

Keywords:

HIV in pregnancy, vertical transmission, antiretroviral therapy, pregnant women, opportunistic infections.

Abstract

Human Immunodeficiency Virus Infection in pregnancy is a global health problem that may increase morbidity and mortality risks for both mother and infant. Mother-to-child transmission of HIV can occur during pregnancy, delivery, or breastfeeding. Risk factors influencing transmission include high maternal viral load, lack of antiretroviral therapy, opportunistic infections, and certain obstetric conditions. Clinical manifestations in pregnant women with HIV vary from asymptomatic conditions to severe opportunistic infections due to immune system suppression. Diagnosis is established through serological testing and viral load examination to assess the severity of infection. Management of HIV in pregnancy focuses on optimal antiretroviral therapy, monitoring maternal and fetal conditions, and preventing vertical transmission. With early detection and adequate therapy, the risk of mother-to-child HIV transmission can be significantly reduced, thereby improving the quality of life of both mother and child.

Downloads

Download data is not yet available.

References

POGI. Pedoman Nasional Pelayanan Kedokteran: Hipertensi dalam Kehamilan. Jakarta: Perkumpulan Obstetri dan Ginekologi Indonesia; 2022.

Cunningham FG, Leveno KJ, Bloom SL, et al. Williams Obstetrics. 26th ed. New York: McGraw-Hill Education; 2022.

American College of Obstetricians and Gynecologists (ACOG). Gestational Hypertension and Preeclampsia. ACOG Practice Bulletin No. 222. Obstet Gynecol. 2020;135(6):e237–e260.

World Health Organization. WHO recommendations on the prevention and treatment of pre-eclampsia and eclampsia. Geneva: WHO; 2023.

Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia 2022. Jakarta: Kemenkes RI; 2023.

Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia. Int J Gynecol Obstet. 2021;155(Suppl 1):3–15.

Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy (ISSHP) classification. Pregnancy Hypertension. 2022; 27:148–169.

Roberts JM, Escudero C. The placenta in preeclampsia. Placenta. 2021; 102:21–27.

Redman CWG, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol. 2023;228(2): S822–S833.

Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2021; 374:13–22.

Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification and management recommendations. Hypertension. 2022; 79:168–185.

Duley L, Meher S, Abalos E. Management of pre-eclampsia. BMJ. 2021;374: n1894.

Mol BWJ, Roberts CT, Thangaratinam S, et al. Pre-eclampsia. Lancet. 2023;401(10377):411–426.

POGI. Rekomendasi Praktik Klinis Obstetri dan Ginekologi. Jakarta: POGI; 2023

McKinney D, Boyd H, Langager A, et al. The impact of antenatal corticosteroids on neonatal outcomes. Obstet Gynecol. 2021;137(2):311–320.

Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health. Circulation. 2022; 145:117–130.

Hofmeyr GJ, Manyame S, Medley N, et al. Calcium supplementation during pregnancy for preventing hypertensive disorders. Cochrane Database Syst Rev. 2023; Issue